Efgartigimod Treatment Increases Spending for CIDP Patients
A new study has found that introducing efgartigimod alfa as a treatment option in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) who are currently receiving subcutaneous immune globulin (IG) or intravenous IG would result in substantially increased spending in the treatment of CIPD.
COVID-19 Vaccine Tied to Increased Survival in Patients with Cancer
A study has found that for patients with certain types of advanced lung or skin cancer, administration of a SARS-CoV-2 mRNA vaccine within 100 days of starting immune checkpoint inhibitors is associated with increased overall survival.
RSV Poses Significant Threat to Patients with Systemic Autoimmune Rheumatic Diseases
A retrospective cohort study has found respiratory syncytial virus infections are associated with substantial morbidity among patients with systemic autoimmune rheumatic diseases, with more than half of infected individuals requiring hospitalization.
Study Finds Viral Infections Increase Risk of Heart Attack/Stroke
A new study has found people have an increased risk of major cardiovascular events following viral infections such as SARS-CoV-2, influenza, HIV, hepatitis C and varicella zoster virus.
Study Shows Hormone Therapy Is Linked to Autoimmune Disease
A recent study shows the use of hormone therapy in postmenopausal women was associated with a significantly higher incidence and risk of autoimmune diseases.
Takeda’s HyHub and HyHub Duo Devices Now Available in the U.S.
The HyHub and HyHub Duo devices are now available in the U.S. for patients 17 years of age and older who are prescribed HYQVIA.
Grifols Withdraws Four Lots of Gamunex-C 10%
Grifols Therapeutics has initiated a voluntary withdrawal of four lots of Gamunex-C 10%.
FDA Accepts NDA for Leniolisib to Treat Children with APDS
FDA has accepted a supplemental new drug application for leniolisib to treat activated phosphoinositide 3-kinase delta syndrome, or APDS, in children aged 4 to 11 years.
COVID mRNA Vaccine Induces Immune Response Against Cancer
New research has found that patients with advanced lung or skin cancer who received a COVID-19 mRNA vaccine within 100 days of starting immunotherapy drugs lived significantly longer than those who did not get the vaccine.
FDA Approves Libtayo for Cutaneous Squamous Call Carcinoma
The U.S. Food and Drug Administration has approved Libtayo (cemiplimab-rwlc) for the adjuvant, or postsurgical, treatment of adults with cutaneous squamous cell carcinoma at high risk of recurrence after surgery and radiation.